Related Experiment Video

Updated: Mar 29, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual

Ruo-Hui He1,2,3, Yi-Jing He1,2,3, Yong-Jun Tang1,2,3

  • 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P.R. China.

Pharmacogenomics
|December 15, 2015
PubMed

Insights

Beta-adrenergic receptors (β-ARs) play a role in cancer, and β-AR blockers show promise in cancer therapy. Further research into their molecular mechanisms and genetic impacts is crucial for treatment optimization.

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Beta-adrenergic receptors (β-ARs) are widespread in tissues and activated by neurotransmitters.
  • These receptors mediate physiological functions and are implicated in abnormal states like cancer.
  • Beta-adrenergic receptor blockers are emerging as potential cancer therapeutics, but mechanisms remain unclear.

Purpose of the Study:

  • To elucidate the molecular mechanisms of beta-adrenergic receptor signaling in cancer.
  • To understand how beta-blockers exert their effects in cancer treatment.
  • To explore the role of genetic variations in the beta-adrenergic system in cancer.

Main Methods:

  • Identification of β-AR system signal pathways relevant to cancer.
  • Analysis of retrospective clinical data on β-blocker use in cancer patients.
  • Genetic studies investigating the effects of β-adrenergic system polymorphisms on cancer.

Main Results:

  • Retrospective clinical data support the efficacy of β-blockers beyond cardiovascular disease, indicating potential in cancer therapy.
  • Identification of key signaling pathways provides insight into β-blocker mechanisms in cancer.
  • Genetic studies highlight the influence of β-adrenergic system polymorphisms on cancer susceptibility, treatment response, and prognosis.

Conclusions:

  • Understanding β-AR signaling pathways is essential for comprehending β-blocker action in cancer.
  • Clinical and genetic data strengthen the rationale for using β-blockers in cancer treatment.
  • Further investigation into genetic factors can refine personalized cancer therapy strategies.
Keywords:
cancer progressionpolymorphismstumor biology behaviorsβ-adrenergic receptorsβ-blockers

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

25.0K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
94
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K